c-Kit (V560G)

KIT · Variant type: point · HGVS: p.V560G

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	99.5%	0.5%	78.23
2	Tivozanib	99.2%	0.8%	92.42
3	Avapritinib	99.0%	1.1%	97.73
4	Ripretinib	98.9%	1.1%	92.95
5	Dasatinib	98.6%	1.4%	87.97
6	Nintedanib	98.6%	1.4%	90.23
7	Erdafitinib	97.8%	2.2%	95.71
8	Sorafenib	97.1%	2.9%	96.72
9	Brigatinib	95.2%	4.8%	82.96
10	Selpercatinib	95.0%	5.0%	96.72
11	Cabozantinib	94.4%	5.6%	92.73
12	Apatinib	93.9%	6.1%	97.73
13	Pacritinib	93.4%	6.6%	88.64
14	Nilotinib	93.3%	6.7%	96.49
15	Umbralisib	90.5%	9.5%	98.74
16	Regorafenib	89.3%	10.7%	95.99
17	Pralsetinib	88.4%	11.6%	93.43
18	Axitinib	88.3%	11.7%	93.23
19	Gilteritinib	87.2%	12.8%	88.97
20	Quizartinib	83.0%	17.0%	99.50
21	Sunitinib	81.7%	18.3%	91.73
22	Vandetanib	81.1%	18.9%	95.74
23	Fostamatinib	79.8%	20.2%	96.74
24	Upadacitinib	78.8%	21.2%	97.98
25	Fedratinib	78.7%	21.3%	96.21

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	99.5%	—	—
Tivozanib	99.2%	—	—
Avapritinib	99.0%	—	—
Ripretinib	98.9%	—	—
Dasatinib	98.6%	—	—
Nintedanib	98.6%	—	—
Erdafitinib	97.8%	—	—
Sorafenib	97.1%	—	—
Brigatinib	95.2%	—	—
Selpercatinib	95.0%	—	—
Cabozantinib	94.4%	—	—
Apatinib	93.9%	—	—
Pacritinib	93.4%	—	—
Nilotinib	93.3%	—	—
Umbralisib	90.5%	—	—
Regorafenib	89.3%	—	—
Pralsetinib	88.4%	—	—
Axitinib	88.3%	—	—
Gilteritinib	87.2%	—	—
Quizartinib	83.0%	—	—
Sunitinib	81.7%	—	—
Vandetanib	81.1%	—	—
Fostamatinib	79.8%	—	—
Upadacitinib	78.8%	—	—
Fedratinib	78.7%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.7ms